VIP Peptide: Benefits, Evidence, and Real Risks

VIP was isolated from intestinal tissue and named for the first thing it was seen doing: dilating blood vessels. It is 28 amino acids long and belongs to the secretin/glucagon superfamily, which makes it a structural cousin of PACAP, secretin, and glucagon.

It signals through two class B G-protein-coupled receptors, VPAC1 and VPAC2, both of which bind VIP with high affinity and require the entire 28-residue peptide for full engagement (Couvineau & Laburthe, Br J Pharmacol, 2012). A third receptor, PAC1, binds VIP only weakly.

Those two receptors are scattered across very different tissues, which is why one peptide produces such an unrelated-looking list of effects. Airway smooth muscle relaxes. Intestinal epithelium secretes water and electrolytes. T cells shift toward a regulatory phenotype (Delgado & Ganea, Amino Acids, 2013). In the suprachiasmatic nucleus, VIP holds the clock neurons in phase with each other; mice lacking it lose behavioural rhythmicity (Aton et al., Nature Neuroscience, 2005).

One pharmacological fact governs everything downstream. Circulating VIP survives roughly one to two minutes before peptidases destroy it. Even inhaled synthetic VIP produced pulmonary vasodilation that was "modest and short-lived" (Leuchte et al., Eur Respir J, 2008). A molecule that disappears that fast was built for local paracrine signalling, not for circulating hormone duty. If you want to see how peptide half-lives shape dosing schedules, the peptide half-life tracker makes the arithmetic visible.

Picture a stadium PA system announcing "clear the concourse." The groundskeeper starts sweeping. Security walks the aisles. The kitchen crew locks the shutters. Same broadcast, three unrelated actions, because each crew is trained to hear that phrase differently.

VIP works the same way. It is one signal, released from nerve terminals and immune cells, and what happens next depends entirely on which receptor the receiving tissue carries and what that tissue is wired to do. VPAC1 predominates in the gut epithelium and liver. VPAC2 predominates in vascular and airway smooth muscle, pancreatic beta cells, and clock neurons.

Literally: VIP has no single effect. Its output is determined by VPAC1 and VPAC2 distribution across tissues, and both receptors couple to adenylate cyclase, raising intracellular cAMP in whatever cell they sit on. Relaxation in a muscle cell, secretion in a gut cell, suppression in a T cell.

That is the mechanism behind the sprawling benefit lists you see on peptide vendor pages. Vasodilation, bronchodilation, gut secretion, inflammation control, and sleep-wake timing are all real VIP biology. None of them are the same thing as a clinical benefit from a supplemented dose.

Almost all consumer search interest in VIP traces to one source. Dr Ritchie Shoemaker built a treatment protocol for what he named Chronic Inflammatory Response Syndrome (CIRS), a multi-system illness he attributes to biotoxin exposure in water-damaged buildings. Intranasal VIP is the final step in that protocol.

The claim is specific. Compounded VIP nasal spray at 50 mcg per spray, four to eight sprays daily, is said to normalise MMP-9, TGF-beta-1, C4a, and VEGF, restore pituitary axis regulation, and even reverse grey matter atrophy on MRI.

The evidence for that claim is three publications: a 2013 paper in *Health*, a 2016 paper in *Medical Research Archives*, and a 2017 paper in *Internal Medicine Review*. Shoemaker is an author on all three. None is randomised. None has a placebo group. None appears in PubMed. Searching PubMed for Shoemaker plus vasoactive intestinal peptide returns two papers from the 1980s by a different author entirely.

The diagnostic category itself sits outside mainstream medicine. Allergy and immunology bodies recognise that indoor mold causes asthma exacerbation, allergic rhinitis, and hypersensitivity pneumonitis, and have found no support for a distinct multi-system biotoxin illness (Bush et al., J Allergy Clin Immunol, 2006). CIRS has no ICD code and no professional-society guideline.

None of that proves the protocol does nothing. It means the protocol has never been tested in a way that could tell the difference between the drug and the expectation of the drug. Compounded peptides also sit in a shifting regulatory zone; see are peptides legal for where nasal-spray compounding currently stands.

Synthetic VIP has a generic name, aviptadil, and it has been through real trials. Those trials are the closest thing to a clean read on whether supplementing VIP does anything.

COVID-19 respiratory failure. The TESICO trial randomised 461 patients with COVID-associated hypoxaemic respiratory failure to intravenous aviptadil or placebo, escalating from 600 to 1,800 pmol/kg over three days. The odds ratio for a better outcome at day 90 was 1.11 (95% CI 0.80 to 1.55, p = 0.54). Mortality was 38% on aviptadil versus 36% on placebo. The data and safety monitoring board stopped the aviptadil arm for futility (Brown et al., Lancet Respir Med, 2023).

A 2025 systematic review pooled the randomised evidence in ARDS and found a survival odds ratio of 1.01 (95% CI 0.72 to 1.42, p = 0.93). The seven uncontrolled case series in the same review reported 88.9% survival (Udupa et al., Indian J Crit Care Med, 2025). Hold those two numbers next to each other. The controlled data say nothing happened. The uncontrolled data look spectacular. Aviptadil has never been FDA approved for any indication.

Sarcoidosis. Twenty patients inhaled nebulised VIP for four weeks in an open-label phase II study. TNF-alpha production by bronchoalveolar cells fell significantly and regulatory T cells rose (Prasse et al., Am J Respir Crit Care Med, 2010). Real immunological movement, no control arm, no clinical outcome.

Pulmonary hypertension. Eight patients with primary pulmonary hypertension received inhaled VIP in an open-label study; mean pulmonary artery pressure fell and cardiac output rose (Petkov et al., J Clin Invest, 2003). A later acute study in 20 patients found the pulmonary vasodilation real but small and temporary (Leuchte et al., Eur Respir J, 2008). Two decades on, no approved VIP therapy for pulmonary hypertension exists.

The pattern repeats across every indication. Mechanism, yes. Surrogate markers, sometimes. Patient outcomes in a controlled trial, no.

Medicine already ran the experiment on sustained high VIP. It is called a VIPoma, a rare neuroendocrine tumour that secretes VIP without a brake. No competitor page discussing "VIP benefits" mentions it.

Normal fasting plasma VIP sits below about 70 pg/mL. A VIPoma is diagnosed above roughly 203 pg/mL, and the median value in confirmed cases is around 630 pg/mL, about nine times the upper limit of normal, with reported values running far higher (de Herder & Hofland, VIPoma, Endotext (NCBI Bookshelf)).

At those concentrations, VPAC1 receptors on the intestinal epithelium never stop firing. A healthy adult loses roughly 100 to 200 mL of water per day in stool. A severe VIPoma patient passes 6 to 8 litres, a 30- to 60-fold increase, and the diarrhoea continues through fasting. Potassium and bicarbonate leave with it, producing hypokalaemia and metabolic acidosis. Gastric acid secretion shuts down, giving achlorhydria. That triad is the syndrome. Roughly half of patients also develop hypercalcaemia, and 15% to 30% flush (Karele & Solis, Presse Med, 2024). Five-year survival is above 90% when the tumour is localised and about 60% once it has metastasised.

The honest reading: a 50 mcg intranasal spray does not reproduce a VIPoma. Circulating VIP clears in one to two minutes, and nasal absorption is a fraction of the dose. What VIPoma establishes is the direction of travel and the tissue that breaks first. Sustained VIP receptor agonism empties the gut, dumps potassium, and stops acid secretion. Anyone escalating VIP on their own, dosing eight sprays a day for months, or stacking it with other secretory agents should know which organ writes the first warning. New watery diarrhoea, muscle weakness, or cramping on a VIP protocol means stop the spray and call your doctor. The same logic applies to any peptide that acts on gut secretion and motility.

The second harm is financial, and the numbers are easy to run. Compounded VIP nasal spray sells through telehealth and compounding pharmacies for roughly $189 to $439 per month. The Shoemaker protocol positions VIP as a final step used for months, and clinicians describe treatment windows beyond 12 weeks at more than six doses per day.

Take the low end. Twelve months at $189 is $2,268. Add the CIRS lab panel that gates entry to the protocol (C4a, TGF-beta-1, MMP-9, VEGF, MSH, VCS testing), typically several hundred to over a thousand dollars, largely uninsured. Add the prerequisite steps, binders, nasal antibiotics, remediation. A complete run past $4,000 is ordinary. At the $439 tier, twelve months alone is $5,268.

Now price the evidence you are buying. Zero randomised controlled trials. Zero placebo comparisons. Three uncontrolled reports, all co-authored by the protocol's originator, none indexed in PubMed. The one large placebo-controlled trial of synthetic VIP in humans enrolled 461 patients, found an odds ratio of 1.11 with a confidence interval crossing 1, and was halted for futility.

Contrast that with the "over 10,000 patients treated" figure cited in protocol marketing. Ten thousand uncontrolled treatments cannot answer the only question that matters, because there is no group of ten thousand who took the placebo. The 2025 ARDS review is a clean demonstration: case series showed 88.9% survival and the randomised data showed an odds ratio of 1.01. Same drug, opposite stories, and only one of them controlled for who gets better anyway.

Before committing, price the full course honestly with the peptide cost calculator, and compare against what peptide therapy costs across the field.

This skill generalises far beyond VIP. Peptide medicine is full of protocols whose citation list is a case series written by the person selling the protocol. Six questions expose them in about fifteen minutes.

1. Find the actual citation, not the claim. Vendor pages say "clinically proven" and link to nothing. Demand the author, journal, year. If the page cannot produce one, the audit is already over.

2. Search the citation in PubMed. Go to pubmed.ncbi.nlm.nih.gov and search the exact title. Indexing is not a guarantee of quality, but absence from PubMed means the journal cleared no indexing standard at all. All three VIP/CIRS papers fail here.

3. Ask what the control group did. A study without a control group cannot separate the drug from regression to the mean, from remediation of the mold exposure, from placebo response, or from time. Every uncontrolled series looks like a miracle. The aviptadil case series reported 88.9% survival and the randomised trials found no survival benefit at all.

4. Check who authored it against who profits. When the trial author, the diagnostic criteria author, the certifying body, and the treatment vendor are the same network, no independent party has ever tried to falsify the claim.

5. Look for a single independent replication. One outside group, no financial stake, same result. For intranasal VIP in CIRS, after roughly eighteen years, there is none.

6. Check the outcome measure. "Normalises C4a and TGF-beta-1" is a surrogate the protocol's author selected and interprets. "Fewer deaths at day 90" is an outcome nobody can spin. Surrogate improvement with no outcome data is where most peptide claims live.

Run those six on any peptide before you buy it. Run them on the vendor too; where to buy peptides in 2026 covers the sourcing side, and getting started with peptides covers the rest.

Every widely marketed VIP claim, the setting it was tested in, the strongest evidence that exists, and the verdict.

Read that table as two blocks. The bottom half is textbook physiology nobody disputes. The top half is what people are being sold. Very little travels from one block to the other, which is the ordinary fate of most endogenous signalling molecules when they are given as drugs. Compare with better-supported immune peptides such as thymosin alpha-1 and LL-37.

Mistake 1: Treating "your body already makes it" as a safety argument. Your body makes VIP at picomolar concentrations, in nerve terminals, for one to two minutes at a time. Insulin is also endogenous, and a wrong dose kills. Endogenous origin says nothing about the safety of an exogenous dose eight times a day for a year. The fix: judge a dose by trial data, not by provenance.

Mistake 2: Reading "10,000 patients treated safely" as evidence it works. Safety in an uncontrolled population and efficacy are different questions, and neither is answered without a comparison group. The 2025 ARDS review put the two side by side: 88.9% survival in case series, an odds ratio of 1.01 in the randomised data. The fix: ask for the control arm before you ask for the testimonial.

Mistake 3: Believing the aviptadil press releases and ignoring the trial. Company statements in 2021 described a 35% higher likelihood of recovery. The federally funded randomised trial that followed enrolled 461 patients and was stopped for futility, with mortality of 38% versus 36%. Serious adverse events by day 5 ran 63% on aviptadil against 56% on placebo, a difference that did not reach significance but pointed the wrong way. The fix: weigh the day-90 endpoint above the press release.

Mistake 4: Buying research-grade VIP powder and dosing it nasally. Unregulated powder carries no purity, sterility, or content assurance, and VIP is fragile enough that handling and storage errors silently destroy the peptide before it reaches you. Nasal delivery of a self-reconstituted peptide adds a mucosal infection route. The fix: if you pursue VIP at all, do it through a licensed prescriber and a compounding pharmacy, and read how to store peptides first. Check combinations with the peptide interaction checker.